Therapeutic potential of living donor liver transplantation from heterozygous carrier donors in children with propionic acidemia

Zhi-Gui Zeng1,3†, Guang-Peng Zhou1,3†, Lin Wei1,3, Wei Qu1,3, Ying Liu1,2,3, Yu-Le Tan1,3, Jun Wang1,3, Li-Ying Sun1,2,3* and Zhi-Jun Zhu1,3*

Abstract

Background: Current world experience regarding living donor liver transplantation (LDLT) in the treatment of propionic acidemia (PA) is limited, especially in terms of using obligate heterozygous carriers as donors. This study aimed to evaluate the clinical outcomes of LDLT in children with PA.

Methods: From November 2017 to January 2020, 7 of the 192 children who underwent LDLT at our institution had been diagnosed with PA (median age, 2.1 years; range, 1.1–5.8 years). The primary indication for transplantation was frequent metabolic decompensations in 6 patients and preventative treatment in 1 patient. Of the seven parental living donors, six were genetically proven obligate heterozygous carriers.

Results: During a median follow-up of 23.9 months (range, 13.9–40.2 months), all patients were alive with 100% allograft survival, and no severe transplant-related complications occurred. In the case of liberalized protein intake, they did not suffer metabolic decompensation or disease-related complications and made progress in neurodevelopmental delay and body growth, as well as blood and urinary metabolite levels. In one patient with pre-existing mild dilated cardiomyopathy, her echocardiogram results completely normalized 13.8 months post-transplant. All living donors recovered well after surgery, with no metabolic decompensations or procedure-related complications. Western blotting revealed that the hepatic expressions of PCCA and PCCB in one of the heterozygous donors were comparable to those of the normal healthy control at the protein level.

Conclusions: LDLT using partial liver grafts from asymptomatic obligate heterozygous carrier donors is a viable therapeutic option for selected PA patients, with no negative impact on donors’ and recipients’ clinical courses.

Keywords: Propionic acidemia, Living donor liver transplantation, Heterozygous carrier, Propionyl-CoA carboxylase

Introduction

Propionic acidemia (PA; Online Mendelian Inheritance in Man (OMIM) #606054) is an ultrarare autosomal-recessive disorder of metabolism characterized by biallelic pathogenic variants on chromosome 13q32.3 (PCCA) or 3q22.3 (PCCB), resulting in the deficiency of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) [1]. Dysfunction of PCC fails to convert propionyl-CoA to methylmalonyl-CoA, thereby leading to the chronic accumulation of propionic acid and...
propionyl-CoA-related metabolites. These circulating toxic metabolites continuously cause damage to various organs and tissues throughout the body [2]. Since compound heterozygotes in most patients result in undefined genotype–phenotype correlation, affected individuals present with a broad spectrum of clinical manifestations, and age of onset ranges from the neonatal period to adulthood [3]. Characteristic patients usually present in infancy with poor feeding and episodic vomiting within the first few hours to days of life. Without prompt diagnosis and treatment, the illness can progress rapidly to severe ketoacidosis, hyperammonemia, and hyperlactatemia, manifesting as lethargy, seizure, or coma that can result in early death [4, 5]. Despite good compliance with long-term conservative management consisting of individualized nutritional intervention, levocarnitine supplementation, and oral metronidazole, the overall prognosis of PA patients remains poor [6]. Patients surviving their initial metabolic decompensation episode may suffer frequent metabolic decompensations and disease-related long-term multiorgan sequelae such as growth impairment, neurocognitive deficits, cardiomyopathy, pancreatitis, or chronic kidney disease [7, 8]. Furthermore, PA patients’ lifelong high-intensity medical and dietary management demands can severely affect family life and cause tremendous financial and psychosocial stress to patients’ caregivers [9, 10].

Since replacing the enzyme-deficient liver with a metabolically normal liver could help regain partial PCC activity, after the first attempt in 1991, liver transplantation (LT) has emerged as a novel therapeutic option for selected PA patients who, despite strict dietary and medical intervention, still experience frequent metabolic decompensations or cardiomyopathy [11–15]. In some centers, early LT has been offered as a preventative treatment for metabolically stable pediatric PA patients without metabolic decompensation and severe neurological or cardiac sequelae [13, 14, 16].

Living donors, especially in countries with limited availability of deceased donors, are an essential source of donor organs. And parents of liver transplant candidates are often the predominant and even sole source of living donors. This study was reviewed and approved by the Ethical Committee of the Hospital, and all living donors were declare that all cases of LDLT were approved by the Ethical Committee of Hospital (No. 2020-P2-094-01) and conducted according to the ethical guidelines of the Declaration of Helsinki and the Declaration of Istanbul. We declare that all cases of LDLT were approved by the Ethical Committee of the Hospital, and all living donors were voluntary and altruistic.

Results
Patient characteristics
During November 2017 and January 2020, 192 children underwent LDLT at our institution, of whom 7 (3.7%) were diagnosed with PA. According to the age at initial presentation, 3 patients were early-onset (within the first month of life), and the remaining 4 were late-onset (after the first month). The diagnosis of PA was confirmed through a combination of clinical manifestations, typical biochemical findings, and identification of pathogenic variants in PCCA or PCCB on molecular genetic testing (Table 1; Fig. 1). No patients were from consanguineous parents or had a previously affected

Materials and methods
Data collection
Patients with PA who underwent LT at our hospital between November 2017 and January 2020 were identified from the liver transplant recipient database. We retrospectively collected demographic data (gender, age, height, weight, age and features of initial clinical manifestations, age at diagnosis, daily protein intake, and medical therapy); transplantation details (indication for LT, age at LT, donor type, graft type, duration of intensive care unit and hospital stay, and postoperative LT-related complications); and laboratory measures (molecular genetic testing, urine organic acid, blood amino acid analysis, blood acylcarnitine profile, renal function, and echocardiography). The neurodevelopmental delay was assessed using the developmental quotient (DQ), which was calculated using the Griffiths Development Scales-Chinese (GDS-C) and the Wechsler Intelligence Scale for Children-IV (WISC-IV) [17]. The hepatic expressions of PCCA and PCCB were assessed at the protein level by western blotting using antibodies directed against PCCA and PCCB proteins (anti-PCCA rabbit polyclonal antibody (ab154254), anti-PCCB rabbit polyclonal antibody (ab96729), Abcam).

Statistical analysis
Results were expressed as mean±standard deviation or median (range). Paired sample Student’s t test was used for comparative analysis of results before and after transplantation, and P<0.05 was considered a significant difference. Statistical analyses were performed using SPSS software 26.0 (SPSS, Inc., Chicago, IL, USA).

Discussion
Living donors, especially in countries with limited availability of deceased donors, are an essential source of donor organs. And parents of liver transplant candidates are often the predominant and even sole source of living donors. Thus, living donor liver transplantation (LDLT) using an allograft from a heterozygous carrier donor in autosomal-recessive disorders is always inevitable. However, there remains a concern for the potentiality of the insufficient PCC activity in the donor remnant liver and the partial liver graft, and the current world experience of using obligate heterozygous carriers in LDLT for PA patients is limited. Here, we report our single-center experience with LDLT in 7 children with PA, of whom 6 received partial liver grafts from genetically proven heterozygous parental living donors.
Table 1  Demographics, preoperative characteristics, and operative findings of seven recipients with propionic acidemia who underwent LDLT

| Sex | Age at onset/diagnosis | Genetic testing | Initial clinical manifestations | Age at LT, years | Indication for LT | Donor  | Heterozygous donor | Graft type | Graft weight, g | GRWR, % | Operation time, minutes | Blood loss, ml/kg | CIT, minutes | ICU Stay, days | Hospital stays, days | Post transplant complications |
|-----|------------------------|-----------------|--------------------------------|------------------|------------------|--------|-------------------|-----------|------------------|---------|------------------------|-------------------|-------------|-----------------|----------------------|------------------------|
| 1 F | 3 days/5 months        | c.839dupT; c.996_998del in PCCA | Poor feeding, episodic vomiting, lethargy | 1.7             | Frequent MDs    | Mother | Yes (c.996_998del) | Left lateral | 210              | 1.84    | 500                    | 17.5              | 145         | 4               | 33                   | CMV Viremia, EBV Viremia |
| 2 F | 6 months/7 months      | c.30_39del10, c.331C>T in PCCB | Poor feeding, lethargy | 2.1             | Frequent MDs    | Father | Yes (c.30_39del10) | Left lateral | 299              | 2.60    | 390                    | 9.6               | 100         | 4               | 32                   | CMV Viremia, EBV Viremia, Bile leakage |
| 3 M | 6 months/7 months      | c.733G>A in PCCB | Poor feeding, lethargy, muscle hypotonia | 5.8             | Frequent MDs    | Mother | No                | Left lateral | 252              | 1.68    | 525                    | 4.7               | 85          | 5               | 30                   | EBV Viremia          |
| 4 M | 3 months/4 months      | c.1207C>T, c.319G>A in PCCB | Poor feeding, episodic vomiting, lethargy | 1.3             | Frequent MDs    | Father | Yes (c.319G>A) | Reduced-size left lateral | 144            | 1.92    | 385                    | 40.0              | 110         | 6               | 32                   | EBV Viremia          |
| 5 F | 10 days/8 months       | c.2002G>A (homozygous) in PCCA | Poor feeding, episodic vomiting | 2.7             | Frequent MDs and dilated cardiomyopathy | Mother | Yes (c.2002G>A) | Left lateral | 206              | 1.87    | 290                    | 13.6              | 104         | 4               | 12                   | CMV Viremia          |
| 6 M | 6 months/8 months      | c.331C>T, c.493C>T in PCCB | Neurodevelopmental delay | 4.5             | Preventative treatment | Father | Yes (c.331C>T) | Left lateral | 236              | 1.31    | 443                    | 5.6               | 144         | 2               | 13                   | CMV Viremia          |
| 7 M | 21 days/1.5 months     | c.1283C>T, c.390delT in PCCA | Poor feeding, episodic vomiting, lethargy, seizure | 1.1             | Frequent MDs    | Father | Yes (c.390delT) | Left lateral | 205              | 1.99    | 336                    | 8.7               | 138         | 13              | 17                   | CMV Viremia          |

CIT cold ischemia time, CMV cytomegalovirus, d day, EBV Epstein-Barr virus, ICU intensive care unit, GRWR graft-to-recipient weight ratio, LDLT living donor liver transplantation, MDs metabolic decompensations

*There was suspected heterozygous deletion mutation in exon 9 of the PCCB gene
relative. After diagnosis, all patients followed a strict protein-restriction diet, a special formula that contains no isoleucine, methionine, threonine, and valine, and were administered levocarnitine supplementation. Before LT, the median protein restriction was 1.75 g/kg/day (range, 0.8–2.7 g/kg/day), and none required supportive feeding (Table 2).

**Living donor liver transplantation**

Patients underwent LDLT at a median age of 2.1 years (range, 1.1–5.8 years). The indications were frequent metabolic decompensations (6 patients) and preventative treatment (1 patient). All liver grafts were left lateral segments except for one reduced-size left lateral segment, voluntarily donated by their parents. Of the seven parental living donors, six were genetically proven obligate heterozygous carriers (Table 1). All recipients and donors underwent a smooth operation with stable intraoperative metabolic status. Immediate postoperative courses were uneventful, with no metabolic or hepatic decompensation episodes. The median intensive care unit and hospital stays were 4 days (range, 2–6 days) and 30 days (range, 12–33 days), respectively. Immunosuppressive therapy was based on tacrolimus and low-dose corticosteroids. Tacrolimus administration was started the day after LT, and the dose of tacrolimus was dynamically adjusted according to the target whole-blood trough level. The dose of steroids was gradually tapered and withdrawn within the first 6 months after transplantation. With a median follow-up of 23.9 months, all the recipients were alive with 100% allograft survival. Meanwhile, all living donors were discharged from the hospital, recovered well, and reported good working ability after surgery, with no procedure-related complications or metabolic acidosis during the perioperative period and throughout the follow-up period.
Table 2  Pretransplant and posttransplant clinical index of patients with propionic acidemia

| Follow-up time, months | Outcome | Current age, years | Metabolism correcting medication | Protein intake, g/kg/day | Support feeding | Metabolic decompensations | Cardiomyopathy | DQ |
|------------------------|---------|--------------------|----------------------------------|--------------------------|-----------------|--------------------------|----------------|----|
|                        |         |                    |                                  |                          | Pre  | Post  | Pre  | Post  | Pre  | Post  | Pre  | Post  | Pre  | Post  | Pre  | Post  |
| 1                      | 40.2    | Alive              | 5.0                             | Levocarnitine            | N/A  | Normal diet | N    | N     | Y    | N     | N    | N     | 77   | 85   |
| 2                      | 39.8    | Alive              | 5.3                             | Levocarnitine            | 1.25 | Normal diet | N    | N     | Y    | N     | N    | N     | 69   | 74   |
| 3                      | 37.5    | Alive              | 8.9                             | Levocarnitine Sodium bicarbonate | 2.5  | Normal diet | N    | N     | Y    | N     | N    | N     | 54   | 57   |
| 4                      | 23.9    | Alive              | 3.2                             | Levocarnitine            | 0.8  | Normal diet | N    | N     | Y    | N     | N    | N     | 37   | 45   |
| 5                      | 21.6    | Alive              | 4.5                             | Levocarnitine Sodium benzoate Sodium bicarbonate | 2.25 | Normal diet | N    | N     | Y    | N     | Y    | N     | 86   | 90   |
| 6                      | 18.6    | Alive              | 6.1                             | Levocarnitine            | 2.7  | Normal diet | N    | N     | Y    | N     | N    | N     | 92   | 94   |
| 7                      | 13.9    | Alive              | 2.3                             | Levocarnitine            | 1.0  | Normal diet | N    | N     | Y    | N     | N    | N     | 78   | 78   |

DQ developmental quotient, N na, Y yes
H&E staining of the explanted diseased livers revealed normal liver lobules with the central vein, normal hepatic sinusoid, slightly loose and swollen hepatocytes, no hepatocyte necrosis or vacuolar degeneration, no fibrous tissue proliferation, with a few lymphocytes infiltrated in the partial portal area (Fig. 2A–G). The histopathological examination of the implanted donor livers indicated normal liver lobules with the central vein, normal hepatic sinusoid, and no hepatocyte necrosis or degeneration, with no or mild hepatocyte steatosis (Fig. 2H–N).

**Postoperative transplant-related complications**

No recipients developed any vascular complications after LT. A biliary leak was diagnosed in Patient 2, and she was managed conservatively. There was no occurrence of acute or chronic rejection in all 7 recipients during the follow-up period. Cytomegalovirus viremia and Epstein-Barr virus viremia were the most frequent infectious complications, which occurred in 5 and 4 patients, respectively. They all were treated with intravenous or oral ganciclovir. No patient developed suspected or confirmed posttransplant lymphoproliferative disease (PTLD).

**Postoperative metabolic consequences and diet**

There was no occurrence of metabolic decompensation in all 7 recipients during the follow-up period, allowing for progressive dietary protein liberalization without the need for any supplements other than levocarnitine. At the last follow-up, all patients had no formal protein restriction.

As part of the routine examination for patients with PA, propionate metabolites in blood [glycine and propionylcarnitine (C3)] and urine (3-hydroxypropionate, propionylglycine, methylcitrate, and tiglylglycine) were measured to evaluate metabolic improvement after LT. All seven patients, at least once, had blood glycine and C3 levels recorded before and after LT. The mean blood glycine level was 849.17 ± 326.59 μmol/L before LT and significantly decreased to 387.36 ± 119.83 μmol/L after LT. This reduction of 461.81 μmol/L reached a statistical significance (P = 0.028), and the post-transplant mean glycine levels remained below the normal reference range (65.0–450.0 μmol/L). The mean values of blood C3 reduced from 69.12 ± 43.14 μmol/L before LT to 36.10 ± 21.00 μmol/L after LT. This reduction of 33.02 μmol/L did not reach a statistical significance (P = 0.17), and the post-transplant mean C3 levels remained above the normal reference range (1.00–5.00 μmol/L) (Fig. 1).

Six patients had, at least once, urine organic acid assay before and after LT. Compared with pretransplant values, urine 3-hydroxypropionate, propionylglycine, and tiglylglycine mean levels decreased to nearly normal levels after LT, while mean urine methylcitrate increased from 49.17 ± 68.59 mmol/mol Creatinine before LT to 60.81 ± 60.64 mmol/mol Creatinine after LT. However, this increase of 11.64 mmol/mol Creatinine did not reach a statistical significance (P = 0.61), and the post-transplant mean methylcitrate levels remained above the normal reference range (0–1.00 mmol/mol Creatinine) (Fig. 1).

**Postoperative renal, cardiac, and neurological consequences**

Renal function was evaluated by serum creatinine and estimated glomerular filtration rate (eGFR) calculated according to simplified diet modification in renal disease equation. Values of serum creatinine and eGFR were both within the normal ranges in all patients before and after LT (Fig. 3).

As part of regular assessment, echocardiography was performed for all PA patients during the pretransplant evaluation and every 6 months to 1 year during the
post-transplant follow-up. Pre-LT echocardiography was normal in all patients except for Patient 5. She displayed a mild left ventricular dilation and hypokinesia, and the echocardiogram results completely normalized with improved cardiac dilatation and left ventricular function 13.8 months following her transplant. Post-transplant routine echocardiography of other patients was normal. The neurodevelopmental evaluation using DQ indicated that all patients suffered delayed neurological development prior to LT. Notably, the postoperative DQ levels improved or remained stable in all recipients (Table 2). Despite the improvements in neurodevelopmental delay, all our subjects still did not reach the values appropriate for their age.

**Postoperative body growth**

Body growth parameters, namely height and weight Z scores, were collected before and after LT. There were trends indicating an increase in height Z scores (pre-LT, $-0.76 \pm 1.48$; post-LT, $-0.51 \pm 1.23$; $P=0.39$) and a significant difference between preoperative and postoperative values was observed in weight Z scores (pre-LT, $-0.96 \pm 1.19$; post-LT, $-0.21 \pm 1.26$; $P=0.04$) (Fig. 4).

The hepatic expressions of PCCA and PCCB in the heterozygous living donor

The hepatic expressions of PCCA and PCCB in one of the heterozygous parental living donors (Donor 7) were assessed at the protein level and compared to the liver specimens obtained from the PA patient (Patient 7) and a healthy donor. Western blotting using antibodies directed against PCCA and PCCB proteins demonstrated very low levels of PCCA and PCCB in the PA patient’s liver. However, the hepatic PCCA expression in the heterozygous donor was higher than that of the normal control ($P<0.01$), while the levels of PCCB were comparable ($P>0.05$) (Fig. 5).

**Discussion**

To our knowledge, our series of 7 pediatric PA patients treated with LDLT is the largest to date from a single center. Of the 7 parental living donors, 6 were genetically proven obligate heterozygous carriers. In our report, all 7 recipients achieved satisfactory clinical outcomes with 100% patient and graft survival. There was no occurrence of metabolic decompensation, disease-associated long-term extrahepatic sequelae, or severe LT-related complications during a median follow-up period of 23.9 months. Meanwhile, all living donors recovered well after surgery, without metabolic acidosis or procedure-related complications during the immediate and long-term postoperative periods. More importantly, for the first time, we found that at the protein level, the hepatic expressions of PCCA and PCCB in the heterozygous donor were comparable to the healthy donor.

PA is a rare inborn error of mitochondrial metabolism with life-threatening consequences and multiorgan pathology. Despite following a strict protein restriction and pharmacological intervention, PA patients still suffer frequent metabolic decompensations and subsequent devastating long-term complications [6, 7, 18]. As a kind of enzyme replacement therapy, LT has been performed in 67 PA patients with 75 liver grafts to date [10, 11, 13–15, 19–34]. The overall patient and graft survivals were 80.6% and 72.0%, respectively (Table 3). In the present study, despite a relatively short follow-up of 23.9 months...
**Fig. 4** Physical growth parameters (height and weight Z scores) before and after liver transplantation

*P* = 0.39

**Fig. 5** Western blotting using antibodies directed against PCCA and PCCB proteins demonstrate very low hepatic levels of PCCA and PCCB in the PA patient (Patient 7, whose mutation is c.1283C>T, c.839delT in PCCB). The hepatic PCCA expression in the heterozygous donor (Donor 7) was higher than that of the healthy control, while PCCB expression levels were comparable. For all statistical tests, ***p < 0.001 and **p < 0.01 were considered significant. ns not significant.
Table 3  Literature review of liver transplantation for propionic acidemia

| References           | n  | Onset of PA | Indication for LT | Age at LT (years) | Graft type | Follow-up (months) | Post-LT PA-related complications | Post-LT transplant-related complications | Graft survival | Patient survival |
|----------------------|----|-------------|-------------------|-------------------|------------|--------------------|-----------------------------------|----------------------------------------|---------------|-----------------|
| Kayler et al. [34]   | 1  | Early       | n/a               | 3                 | Deceased   | 0.3                | No                                | N/A                                    | 0/1           | 0/1             |
| Yorifuji et al. [33] | 3  | Early (n = 3)| PMC (n = 3)       | 2.2 (12–51)       | Living     | 2.5 (1.8–4.9)      | MD (n = 1)                        | N/A                                     | 3/3           | 3/3             |
| Manzoni et al. [32]  | 1  | Early       | PMC               | 0.7               | Deceased   | 0.8                | No                                | N/A                                     | 1/1           | 1/1             |
| Romano et al. [31]   | 1  | Late        | CM                | 65                | Deceased   | 0.5                | No                                | N/A                                     | 1/1           | 1/1             |
| Amelook et al. [30]  | 1  | Late        | CM                | 16                | Deceased   | >1                 | No                                | N/A                                     | 1/1           | 1/1             |
| Kasahara et al. [29] | 3  | Early (n = 2)| Late (n = 1)      | 2 (0.6–2.2)       | Living     | 1.7 (1.4–3.4)      | No                                | CMV (n = 2)                             | 3/3           | 3/3             |
| Ryu et al. [28]      | 1  | Early       | PMC               | 18                | Living     | 0.01               | MD (n = 1)                        | H/V/O                                   | 0/1           | 0/1             |
| Arrizza et al. [27]  | 1  | Late        | CM                | 22                | Deceased   | 11                 | No                                | N/A                                     | 1/1           | 1/1             |
| Charbit-Hennion et al. [15] | 12 | Early (n = 12) | PMC (n = 8) | 32 (1.1–9.0) | Deceased (n = 12) | 0.39 (0.01–21) | No | BS (n = 1), HAT (n = 4), Primary nonfunction (n = 13), PTLD (n = 2) | 5/17 | 5/12 |
| Honda et al. [26]    | 1  | Early       | PMC               | 40                | Living     | 0.13               | No                                | AMR                                     | 0/1           | 0/1             |
| Silva et al. [25]    | 2  | Early (n = 1) | Late (n = 1)      | 12.5 and 5.5      | Deceased (n = 2) | 4 and 5 | No | N/A | 2/2 | 2/2 |
| Critelli et al. [23] | 2  | Early       | CM (n = 1) preventative (n = 1) | 8.7 and 1.2 | Deceased (n = 2) | 2.5 and 1.7 | No | ACR (n = 2), CMV (n = 1), HAT (n = 1) | 2/2 | 2/2 |
| Moguilevitch et al. [24] | 1  | Early       | PMC               | 40                | Deceased   | 2                  | No                                | N/A                                     | 1/1           | 1/1             |
| Quintero et al. [14] | 6  | Early (n = 3) | Late (n = 3)      | 5.2 (13–75)       | Living (n = 3) | 1.5 (0.5–4.0) | No | HAT (n = 2) | 6/6 | 6/6 |
| Celik et al. [21]    | 1  | Early       | PMC               | 118               | Living (unrelated) | 2.1 | No | HAT (n = 1) | 1/1 | 1/1 |
| Chu et al. [10]      | 2  | n/a         | n/a               | n/a               | n/a        | n/a                | No                                | N/A                                     | 2/2           | 2/2             |
| Pillai et al. [22]   | 8  | Early       | PMC (n = 8)       | 20 (0.4–94)       | Deceased (n = 8) | 5.4 (1.3–17.1) | No | ACR (n = 2), Chronic rejection (n = 1), HAT (n = 1), IVC stenosis (n = 1), Portal vein stenosis (n = 1) | 8/9 | 8/8 |
| Shanmugam et al. [20] | 5  | Early (n = 1) | late (n = 1)      | 28 (0.7–46)       | Living (n = 5) | 2.8 (1.6–4.2) | MD (n = 1) | HAT (n = 1) | 5/5 | 5/5 |

n/a: Not available
Table 3 (continued)

| References             | n | Onset of PA | Indication for LT | Age at LT (years) | Graft type | Follow-up (months) | Post-LT PA-related complications | Post-LT transplant-related complications | Graft survival | Patient survival |
|------------------------|---|-------------|--------------------|-------------------|------------|-------------------|-----------------------------------|------------------------------------------|----------------|-----------------|
| Curnock et al. [13]    | 14| Early (n = 12) | PMC (n = 10)       | 24 (08–71)        | Living (n = 1) | 4.8 (0.1–22.3)    | MD (n = 5)                        | ACR (n = 6), CMV (n = 6), HAT (n = 1), LCR (n = 2), PTLD (n = 1) | 11/16          | 11/14           |
|                        |   | late (n = 1)   | preventative (n = 4) |                   | deceased (n = 13) |                  | CM (n = 4)                        |                                          |                |                 |
|                        |   | n/a (n = 1)    |                    |                   |             |                  |                                   |                                          |                |                 |
| Tuchmann-Durand et al. [19] | 1| Early | PMC and CM | 5 | Deceased (n = 1) | 0.02 | n/a | N/A | 1/1 | 1/1 |

ACR acute cellular rejection, AMR antibody-mediated rejection, BS biliary sepsis, CM cardiomyopathy, HAT hepatic artery thrombosis, HVD hepatic vein obstruction, LCR late cellular rejection, LT liver transplantation, MD metabolic decompensation, n/a not available, PMC poor metabolic control, PTLD posttransplant lymphoproliferative disease

* The indication for liver transplantation in one patient was poor metabolic control and cardiomyopathy
(13.9–40.2 months), our patients’ survival outcomes were excellent, with 100% patient and graft survival rates, which were superior to previous data. These improvements may be attributed to the tremendous advances in surgical technology, medical management, and immunosuppressive agents since the 1990s. Hepatic artery thrombosis (HAT), one of the most life-threatening LT-related complications, is more frequent in pediatric LT, with an estimated rate of 4–8% [35]. However, the overall rate of HAT in historical PA cases was significantly high at 17.5% [11]. Therefore, it was once believed that patients with PA are more prone to develop HAT after LT [14, 15]. Contrary to previous results, none of our patients developed HAT post-transplant, and thus we could not confirm a propensity for developing HAT in the liver transplant recipients with PA. Regarding other LT-related complications, neither our study nor previous studies have found that patients with PA were at higher risk. Therefore, concerns about transplant-related complications should not be an obstacle for PA patients to choose LT as a treatment option.

Frequent metabolic decompensations are the most common complication of PA patients, leading to frequent hospitalizations and impaired quality of life, and even being life-threatening. Thus, poor metabolic control has become the main indication for LT. Previous studies have demonstrated that LT reduces the risk of metabolic decompensation and improves the quality of life of PA patients [13, 14, 22, 29]. In our study, 6 of the 7 recipients received LT due to frequent metabolic decompensations. Despite not all returning to normal levels, in the case of liberalized protein intake, propionate metabolites in our patients’ blood and urine more or less decreased post-transplant. More importantly, no patients suffered further episodes of metabolic decompensation after LT. Therefore, it should be recognized that LT does bring metabolic stability to the already medically fragile PA patients, thereby largely protecting against metabolic decompensation and the need for frequent hospitalizations, which in itself leads to improved quality of life.

Cardiomyopathy, either dilated or hypertrophic, is another common and potentially lethal complication in PA, with an estimated incidence of 9–23% [4, 36]. It also contributes to one of the major causes of mortality in patients with PA [37]. The cardioprotective potential of LT for individuals with PA has been proved that reversal of cardiomyopathy is achieved in all previously reported 11 patients with pre-existing PA-associated cardiomyopathy [15, 20, 23, 25, 27, 29–31]. In line with previous results, one of our patients with pre-existing mild dilated cardiomyopathy displayed a complete recovery of cardiac function after LT. Taken together, LT can be a viable therapeutic option for PA-related cardiomyopathy, and thus severe drug-resistant cardiomyopathy can remain as an indication for LT in patients with PA. Moreover, LT should not be contraindicated in PA patients with severely impaired cardiac function. Devices to stabilize the hemodynamic conditions, such as left ventricular assist device or extracorporeal membrane oxygenation, can be used as a bridge to LT [29, 30].

Neurodevelopmental sequelae are of particular concern in PA patients and the most crucial factor affecting the long-term quality of life. The poor neurocognitive and psychosocial development resulting from metabolic derangement was reported in 43–75% of PA patients [6, 38]. Previous studies suggested that almost all patients presented with neurodevelopmental delay prior to LT made some developmental progress after LT [13, 14, 22]. Our pretransplant neurodevelopmental assessment indicated that all individuals exhibited neurodevelopmental delay. However, LDLT has stabilized each patient’s neurological impairment and even improved neurodevelopmental delay to some extent. Nevertheless, neurodevelopmental delay still exists in all surviving patients, and whether sustained neurological improvement could be expected requires more investigations in a longer follow-up.

Sufficient daily intake of essential and functional amino acids is necessary for normal body growth in children [39]. However, PA patients must follow a strict lifelong protein-restricted diet, resulting in severe amino acid deficiencies, so they are prone to develop body growth retardation [40]. A post-transplant liberalized protein diet means sufficient intake of essential and functional amino acids, which is crucial to correct chronic malnutrition and stimulate body growth in liver transplant recipients with PA. In turn, optimal growth leads to higher protein tolerance, which possibly helps further to reduce the risk of metabolic decompensation after transplantation [40]. In our series, in the case of no formal protein restriction, post-transplant mean height and weight Z scores were both improved compared with the pretransplant levels. However, whether the present patients’ physical growth would catch up to the standard growth curve warrants further long-term follow-up.

Given the shortage of available donor organs and low priority in the waiting list, LDLT has been a feasible choice for inborn errors of metabolism, in which the donor is almost always a blood relative of the patient, and parental donors are preferable [41, 42]. Since most monogenic diseases are inherited in an autosomal recessive fashion, the parent who serves as a living donor is almost always an obligate heterozygous carrier. However, whether using a partial allograft from a heterozygous living donor contributes to sufficient metabolic correction in a homozygous recipient remains a concern. There is a possibility that the implanted
partial liver graft may have low PCC activity, leading to per-
sistent insufficient enzyme activity in the recipient, which
will compromise the therapeutic value of LDLT in PA.
There is also the possibility that the residual liver’s PCC
activity in the heterozygous donor is insufficient, which
may put the donor in danger of disease-related symptoms
and complications. Curnock et al. [13] hold the view that
it should be preferential to use an unrelated LT donor in
patients with PA. In contrast, previous studies suggested
that no mortality or morbidity associated with the use of
heterozygous carrier donors was observed in donors or
recipients [16, 29, 33, 41]. Our study is believed to be the
largest reported series of PA patients receiving partial liver
grafts from genetically proven obligate heterozygous carri-
ers. We demonstrated satisfactory clinical outcomes in all
6 recipients, with no negative impact on both donors’ and
recipients’ clinical courses. More importantly, for the first
time, our study demonstrated that the hepatic expressions
of PCCA and PCCB at the protein level in one of the het-
erozygous parental living donors were equal to those of
the healthy donor. These results clearly indicate that LDLT
using obligate heterozygous carriers as donors is a viable
therapeutic option for PA. An early LT (ideally within the
first year of life) has been considered for younger children
with non-severe PA [13–15], and scheduled LT, according
to the state of the disease, can almost only be performed in
the setting of LDLT. Considering the promising therapeutic
value of LDLT in the treatment of PA, LDLT using obligate
heterozygous carriers as donors could be considered for
selected PA patients, especially in countries with a limited
deceased donor pool.

Although LT can theoretically provide a lifelong sup-
ply of PCC activity within the allograft, successful trans-
plantation does not result in a cure in individuals with
PA due to the ubiquitous enzyme deficiency through-
out the body. Other extrahepatic tissues with remaining
PCC deficiency, such as skeletal muscle, brain, heart,
and kidneys, persistently produce pathognomonic pro-
piionate metabolites after LT [43]. These circulating toxic
metabolites in turn cause damage to the central nervous
system, heart, kidneys, and other organs throughout the
body. Therefore, continued levocarnitine supplemen-
tation in the posttransplant period is advocated for all
patients to enhance the excretion of propionate metabo-
lites. Nevertheless, some liver transplant recipients with
PA have been reported to develop metabolic decompens-
atation, cardiomyopathy, and kidney dysfunction during
long-term follow-up [13–15, 20, 28, 33, 44]. Although
our patients did not experience the above-mentioned
PA-related complications, it is recognized that LT can
only achieve partial clinical improvements of this dev-
astating disease and delay the progression of the dis-
ease or complications but cannot completely change the
natural history of PA. The possibility of post-transplant
non-remission or even chronic progression of the dis-
ease, especially the occurrence of long-term disease-
related complications, should always be kept in mind by
transplant surgeons. And patients’ parents or guardians
should be fully informed of these potential risks before
LT. Lifelong regular follow-up, including metabolic, car-
diac, renal, and neurological monitoring and evaluation,
is necessary for all individuals with PA post-transplant.
An experienced interdisciplinary team consisting of
metabolism physicians, pediatric hepatologists, pediatric
neurologists, pediatric cardiologists, pediatric nephrolo-
gists, pediatric transplantation team, metabolic dieti-
cians, and neurorehabilitation physicians is also essential
for the long-term management of patients with PA.

This study’s limitations included its single-center ret-
rospective nature, small sample size, and relatively short-
term follow-up. Nevertheless, we found for the first time
that the hepatic expressions of PCCA and PCCB in the
heterozygous parental living donor were equal to those
of the healthy donor, which provides a solid foundation
for the clinical use of LDLT from obligate heterozygous
donors in patients with PA.

Conclusion
In summary, our study provides evidence that the hepatic
expressions of PCCA and PCCB from the heterozygous
donor are comparable to those of the healthy control at
the protein level. LDLT using partial liver grafts from
asymptomatic obligate heterozygous carrier donors is a
viable therapeutic option for selected patients with PA,
with no negative impact on both donors’ and recipients’
postoperative courses.

Abbreviations
ACR: Acute cellular rejection; AMR: Antibody-mediated rejection; BS: Biliary
sepsis; CM: Cardiomyopathy; CMV: Cytomegalovirus; DQ: Developmental quo-
tient; EBV: Epstein-Barr virus; eGFR: Estimated glomerular filtration rate; HAT:
Hepatic artery thrombosis; HVO: Hepatic vein obstruction; ICU: Intensive care
unit; GDS-C: Griffiths Development Scales-Chinese; LT: Liver transplantation;
LDLT: Living donor liver transplantation; MDs: Metabolic decompensations;
n/a: Not available; PA: Propionic academia; PCC: Propionyl-CoA carboxylase;
PCC: Poor metabolic control; PTLD: Posttransplant lymphoproliferative dis-

ease; WISC-IV: Wechsler Intelligence Scale for Children-IV.

Acknowledgements
We acknowledge all patients and their families for participating in this study.

Authors’ contributions
Z‑JE and L‑YS conceptualized and designed the study and contributed to data
interpretation. Z‑GZ and G‑PZ participated in designing the study, designed
the data collection instruments, collected data, carried out the initial analyses,
and drafted the initial manuscript. LW, WQ, YL, Y‑LT, and JW participated in
designing the study and coordinated and supervised data collection. All
authors critically reviewed and revised the manuscript, approved the final
manuscript as submitted, and agreed to be accountable for all aspects of the
work.
Funding
This work was supported by grants from Capital's Funds for Health Improvement and Research (Grant/Award Number: 2020-1-2024) and the National Natural Science Foundation of China (Grant/Award Number: 81970562).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Declarations

Ethics approval and consent to participate
Written informed consent was obtained from all participants, and our study was approved by the Ethical Committee of Beijing Friendship Hospital, Capital Medical University (No. 2020-P2-094-01).

Consent for publication
Not applicable.

Competing interests
All authors declare no conflict of interest to disclose.

Author details
1 Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, No. 101 Lu Yuan Dong Road, Tong-Zhou District, Beijing 101100, China. 2 Department of Critical Liver Diseases, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 101100, China. 3 Clinical Center for Pediatric Liver Transplantation, Capital Medical University, Beijing 101100, China.

Received: 5 July 2021   Accepted: 6 February 2022

Published online: 21 February 2022

References
1. Almasi T, Guey LT, Lukacs C, Csetneki K, Voko Z, Zelei T. Systematic literature review and meta-analysis on the epidemiology of propionic acidemia. Orphanet J Rare Dis. 2019;14(1):40.
2. Hongkittichote P, Ah Mew N, Chapman KA. Propionyl-CoA carboxylase—a review. Mol Genet Metab. 2017;122(4):145–52.
3. Kolker S, Garcia-Cazorla A, Valayannopoulos V, Lund AM, Burlina AB, Syktu-Cegielka J, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015;38(6):1041–57.
4. Hajies HA, Jans JIM, Tas SY, Verhoeven-Duf NWM, van Hasselt PM. Pathophysiology of propionic and methylmalonic acidemias. Part 1: complications. J Inherit Metab Dis. 2019;42(5):730–44.
5. Jurecki E, Ueda K, Fraizer D, Rohr F, Thompson A, Hussa C, et al. Nutrition management guideline for propionic acidemia: an evidence- and consensus-based approach. Mol Genet Metab. 2019;126(4):341–54.
6. Grünert SC, Müllerleile S, De Silva L, Barth M, Walter M, Walter K, et al. Propionic acidemia: clinical course and outcome in 55 pediatric and adolescent patients. Orphanet J Rare Dis. 2013;8:
7. Schelchockov OA, Manoli I, Sloan JL, Ferry S, Pass A, Van Ryzin C, et al. Chronic kidney disease in propionic acidemia. Genet Med. 2019;21(2):2850–5.
8. Forny P, Horster F, Balhausen D, Chakrapani A, Chapman KA, Dionisi-Vici C, et al. Guidelines for the diagnosis and management of methylmalonic acidemia and propionic acidemia: first revision. J Inherit Metab Dis. 2021;44(3):566–92.
9. Jiang YZ, Shi Y, Shi Y, Gan LX, Kong YY, Zhu JZ, et al. Methylmalonic and propionic acidemia among hospitalized pediatric patients: a nationwide study. Orphanet J Rare Dis. 2019;14(1):292.
10. Chu TH, Chien YH, Lin HY, Liao HC, Ho HJ, Lai CJ, et al. Methylmalonic acidemia/propionic acidemia—the biochemical presentation and comparing the outcome between liver transplantation versus non-liver transplantation groups. Orphanet J Rare Dis. 2019;14(1):73.
11. Zhou GP, Jiang YZ, Wu SS, Kong YY, Sun LY, Zhu ZJ. Liver transplantation for propionic acidemia: evidence from a systematic review and meta-analysis. Transplantation. 2021;105(10):2272–82.
12. Molena F, Martellini D, Horster F, Kolker S, Tangeras T, de Koning B, et al. Liver and/or kidney transplantation in amino and organic acid-related inborn errors of metabolism: an overview on European data. J Inherit Metab Dis. 2021;44(3):593–605.
13. Curnock R, Heaton ND, Vilca-Melendez H, Dhawan A, Hadzic N, Vara R. Liver transplantation in children with propionic acidemia: medium-term outcomes. Liver Transpl. 2020;26(3):419–30.
14. Quintero J, Molera C, Juampeier J, Redecillas S, Meavilla S, Nunez R, et al. The role of liver transplantation in propionic acidemia. Liver Transpl. 2018;24(12):1736–45.
15. Charbit-Henrion F, Lacaille F, McKiernan P, Girard M, de Lonlay P, Valayannopoulos V, et al. Early and late complications after liver transplantation for propionic acidemia in children: a two centers study. Am J Transplant. 2015;15(3):786–91.
16. Nagao M, Tanaka T, Mori M, Waki S, Horikawa R, Kasahara M. Improved neurologic prognosis for a patient with propionic acidemia who received early living donor liver transplantation. Mol Genet Metab. 2013;108(1):25–9.
17. Li FY, Fu NN, Li QT, Wang GF, Gao L, Zhang X. The Griffiths Development Scales-Chinese (GDS-C): a reliable and valid neurodevelopmental assessment tool in children with ASD aged 3–8 years old in Tianjin, China. Asian J Psychiatr. 2020;52:1144.
18. Riemersma M, Hazebroek MR, Helderman-van, a den Enden GS, Salomon SF, Brouwers M, et al. Propionic acidemia as a cause of adult-onset dilated cardiomyopathy. Eur J Hum Genet. 2017;25(11):1195–201.
19. Tuchmann-Duane C, Thevenet E, Moulin F, Lesage F, Bouchereau J, Oualha M, et al. Administration of gamma-hydroxybutyrate instead of beta-hydroxybutyrate to a liver transplant recipient suffering from propionic acidemia and cardiomyopathy: a case report on a medication prescribing error. JIMRD Rep. 2020;5(1):25–9.
20. Shanmugam NP, Vallamparampll JJ, Reddy MS, Al Said KJ, Al-Thillhi K, Al-Hashmi N, et al. Auxiliary partial orthotopic liver transplantation for monogenic metabolic liver diseases: single-centre experience. JIMRD Rep. 2019;4(2):29–36.
21. Celik N, Squires JE, Soltyts K, Vockley J, Sholler DA, Chang W, et al. Domino liver transplantation for select metabolic disorders: expanding the living donor pool. JIMRD Rep. 2019;48(1):1839–9.
22. Pillar NR, Stroup BM, Poliner A, Rossetti L, Rawls B, Shyota BJ, et al. Liver transplantation in propionic and methylmalonic acidemias: a single center study with literature review. Mol Genet Metab. 2019;128(4):431–43.
23. Critelli K, McKiernan P, Vockley J, Mazariegos G, Squires RH, Soltyts K, et al. Liver transplantation for propionic acidemia and methylmalonic acidemia: perinatologic management and clinical outcomes. Liver Transpl. 2018;24(9):1260–70.
24. Mogulevitch M, Delphin E. Domino liver transplantation from a child with propionic acidemia to a child with idiopathic fulminant hepatic failure. Case Rep Transplant. 2018;2018:1897495.
25. Silva HM, Nascogne MC, Smets F, Stephenne X, Scheers I, Veyckemans F, et al. Liver transplantation for propionic acidemia. J Pediatr Gastroenterol Nutr. 2017;64(3):e73–6.
26. Honda M, Sakamoto S, Sakamoto R, Matsumoto S, Irie T, Uchida K, et al. Antibody-mediated rejection after ABO-incompatible pediatric living donor liver transplantation for propionic acidemia: a case report. Pediatr Transplant. 2016;20(6):840–5.
27. Arriza C, De Gottardi A, Foglia E, Baumgartner M, Gautschli M, Nuoffer JM. Reversal of cardiomyopathy in propionic acidemia after liver transplantation: a 10-year follow-up. Transpl Int. 2015;28(12):1447–50.
28. Ryu J, Shin YH, Ko JS, Gwak MS, Kim GS. Intractable metabolic acidosis in a child with propionic acidemia undergoing liver transplantation—a case report. Korean J Anesthesiol. 2013;65(3):257–61.
29. Kasahara M, Sakamoto S, Kanazawa H, Karaki C, Kakiuchi T, Shigeta T, et al. Living-donor liver transplantation for propionic acidemia. Pediatr Transplant. 2012;16(3):230–4.
30. Ameloot K, Vlasselaers D, Dupont M, Meersseman W, Desmet L, Vanhaecke J, et al. Left ventricular assist device as bridge to liver transplantation in a patient with propionic acidemia and cardiogenic shock. J Pediatr. 2011;158(5):866–7.
31. Romano S, Valayannopoulos V, Touati G, Jais JP, Rabier D, de Keyzer Y, et al. Cardiomyopathies in propionic aciduria are reversible after liver transplantation. J Pediatr. 2010;156(1):128–34.
32. Manzoni D, Spotti A, Carrara B, Gritti P, Sonzogni V. Anaesthesia for liver transplantation in two infants with an organic acidemia. Pediatr Transplant. 2006;10(5):623–8.
33. Yorifuji T, Kawai M, Mamada M, Kurokawa K, Egawa H, Shigematsu Y, et al. Living-donor liver transplantation for propionic acidemia. J Inherit Metab Dis. 2004;27(2):205–10.
34. Kayler LK, Menon RM, Lee S, Sung RS, Punch JD, Rudich SM, et al. Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant. 2002;6(4):295–300.
35. Kohli R, Cortes M, Heaton ND, Dhawan A. Liver transplantation in children: state of the art and future perspectives. Arch Dis Child. 2018;103(2):192–8.
36. Baumgartner MR, Hörster F, Dionisi-Vici C, Haliloglu G, Karall D, Chapman KA, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130.
37. Kovacevic A, Garbade SF, Hoffmann GF, Gorenflo M, Kolker S, Stauffer C. Cardiac phenotype in propionic acidemia—results of an observational monocentric study. Mol Genet Metab. 2020;130(1):41–8.
38. Fujisawa D, Nakamura K, Mitsubuchi H, Ohura T, Shigematsu Y, Yorifuji T, et al. Clinical features and management of organic acidemias in Japan. J Hum Genet. 2013;58(12):769–74.
39. Lui JC, Garrison P, Baron J. Regulation of body growth. Curr Opin Pediatr. 2015;27(4):502–10.
40. Molema F, Gleich F, Burgard P, van der Ploeg AT, Summar ML, Chapman KA, et al. Decreased plasma l-arginine levels in organic acidurias (MMA and PA) and decreased plasma branched-chain amino acid levels in urea cycle disorders as a potential cause of growth retardation: options for treatment. Mol Genet Metab. 2019;126(4):397–405.
41. Morioka D, Takada Y, Kasahara M, Ito T, Uyuhara K, Ogawa K, et al. Living donor liver transplantation for noncirrhotic inheritable metabolic liver diseases: impact of the use of heterozygous donors. Transplantation. 2005;80(5):623–8.
42. Jiang YZ, Sun LY, Zhu ZJ, Wei L, Qu W, Zeng ZG, et al. Perioperative characteristics and management of liver transplantation for isolated methylmalonic acidemia—the largest experience in China. Hepatobiliary Surg Nutr. 2019;8(5):470–9.
43. Chapman KA, Summar ML, Enns GM. Propionic acidemia: to liver transplant or not to liver transplant? Pediatr Transplant. 2012;16(3):209–10.
44. Sivananthan S, Hadžić N, Dhawan A, Heaton ND, Vara R. Fatal metabolic stroke in a child with propionic acidemia 11 years post liver transplant. Am J Transplant. 2021;21(4):1637–40.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.